Core Insights - Mineros S.A. is making significant progress on its expansion initiatives in Nicaragua, focusing on increasing operational capacity and exploration efforts [1] Group 1: Expansion Initiatives - The company is phasing the expansion of Hemco's main processing plant to reach a capacity of 2,500 tonnes per day (tpd) by the end of the year [1] - There is an acceleration in underground mine development activities [1] - The company has initiated its most aggressive exploration drilling program in the history of the property located in Nicaragua's Autonomous Region [1]

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years [Accessibility Statement] Skip NavigationWASHINGTON, March 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a formal evidentiary public hearing to review the Center for Drug Evaluation and Research's (CDER) proposal to refuse approval of Vanda's supplementa ...

Core Insights - Major banks are increasingly entering the crypto custody space, with Morgan Stanley, Citigroup, and Barclays making significant announcements in the past week [2][3][4]. Group 1: Company Announcements - Morgan Stanley filed for a national trust bank charter to establish Morgan Stanley Digital Trust, which will offer custody, trading, swaps, staking, and stablecoin issuance [3]. - Citigroup plans to launch institutional Bitcoin custody this year, allowing clients to hold Bitcoin alongside traditional assets like equities and bonds [4]. - Barclays is seeking technology providers for a blockchain payment platform that will support stablecoins and tokenized deposits, with a vendor selection target set for April [4]. Group 2: Strategic Implications - Morgan Stanley has $8 trillion in assets under management (AUM), with a significant portion of its client base already holding crypto off-platform, indicating a potential for increased in-house crypto holdings [6]. - The trust bank structure proposed by Morgan Stanley will enable it to compete directly with established crypto custody firms like Coinbase Custody, BitGo, and Anchorage [8]. - Citigroup's initiative to make Bitcoin "bankable" reflects a broader trend of traditional financial institutions integrating cryptocurrency services into their offerings [5].

Core Insights - Absci Corporation has appointed Dr. Ransi Somaratne as Chief Medical Officer to lead the clinical development of its AI-designed therapeutics pipeline, marking a significant step in the company's growth [1][3] - The company also announced the retirement of Professor Andreas Busch, who will continue to contribute as co-chair of Absci's Scientific Advisory Board [1][4] Group 1: Leadership Changes - Dr. Ransi Somaratne, previously Senior Vice President of Clinical Development at Vertex Pharmaceuticals, brings extensive experience in biopharmaceuticals to Absci [2][3] - Professor Andreas Busch, the current Chief Innovation Officer, will retire on March 31, 2026, after playing a crucial role in developing Absci's AI-designed therapeutics, particularly the ABS-201 program [4][5] Group 2: Clinical Development Focus - Dr. Somaratne will oversee the clinical development strategy for Absci's expanding pipeline, which includes the flagship ABS-201 program aimed at addressing significant unmet clinical needs [3][4] - The ABS-201 program is positioned as a groundbreaking innovation for hair regrowth and is also being explored as a potential treatment for endometriosis [5] Group 3: Company Overview - Absci is focused on advancing drug discovery through generative design, utilizing an Integrated Drug Creation™ platform that combines AI models with synthetic biology [5] - The company aims to create innovative therapeutics more rapidly, leveraging a continuous feedback loop between AI algorithms and wet lab validation [5]

Core Insights - Rein Therapeutics has initiated the first patient dosing in its Phase 2 clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF), a severe lung disease with limited treatment options [1][4] Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [7] - The lead product candidate, LTI-03, is a synthetic peptide designed to mimic Caveolin-1, aiming to regulate multiple fibrosis pathways and support lung function [6][7] Clinical Trial Details - The Phase 2 trial is a randomized, double-blind, placebo-controlled study involving approximately 120 patients across multiple countries, with interim data expected in the second half of 2026 [2][3] - The trial will assess safety, tolerability, and changes in lung function, specifically measuring forced vital capacity (FVC) [3] Market Context - IPF affects around 100,000 individuals in the U.S. annually, characterized by lung tissue scarring and a median survival of three to five years post-diagnosis [5]

Group 1 - Fidelity Investments launched two new suites of turnkey model portfolios focused on private market investments, providing exposure to private equity, private credit, and private real estate [1][2] - The portfolios are available to eligible RIAs and broker/dealers through the Envestnet platform, with plans to expand availability to additional platforms in the coming months [2] - The launch is in response to increasing individual investor interest in private market allocations, prompting asset managers to create various products for private wealth and retirement spaces [3] Group 2 - Wealth managers are recognizing the potential of private markets to differentiate their practices and diversify portfolios, although they often face challenges with research and due diligence [3] - Fidelity's new turnkey portfolios complement previous launches of custom portfolios that combined traditional investments with private market assets [3] - Concurrently, Fidelity introduced Alternative NavigatorSM, an education program for advisors to learn about alternative investments, featuring sessions with portfolio construction and alternative investment strategists [4]

Core Insights - Kustom Entertainment's legacy video solutions business has secured a three-year subscription order from a major health system in the Kansas City area, marking its entry into one of the largest integrated health systems in the U.S. [1][4] Group 1: Order Details - The order includes 68 FirstVu Pro body-worn cameras and 9 docking systems, along with a cloud-based service component under a three-year subscription contract [2][4] - This deployment aims to enhance security and safety for patients, employees, and guests by documenting interactions and providing objective records of unusual events [2] Group 2: Company Strategy and Market Position - The CEO of Kustom Entertainment highlighted the growing demand for accountability and safety in the healthcare sector, emphasizing the company's commitment to supporting health systems in providing safe environments [3] - The Kansas City-based health system operates 24 hospitals, employs nearly 48,000 people, and generates over $12 billion in annual revenue, indicating a significant market presence [4] Group 3: Product Features - The FirstVu Pro technology features include 1080p HD video recording, live-streaming capabilities, integrated GPS/Wi-Fi, and durability with IP67 rating for water and dust protection [5][8] - The eight-bay docking systems facilitate rapid data offload and charging, ensuring cameras are ready for use [8]

For more details about FactSet's banking solutions, visit: https://www.factset.com/marketplace/catalog/product/complyadvantage. About FactSet NORWALK, Conn., March 03, 2026 (GLOBE NEWSWIRE) -- FactSet (NYSE:FDS | NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, today announced the launch of integrated AI- driven financial crime risk management capabilities within FactSet's Workstation. These new features— inclusive of Know Your Customer (KYC), Anti-Money Laundering (AML), ...

Echocardiography outcomes show treated patients having reduced negative remodeling of heart volumes SUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported late breaking echocardiography results from its Phase III clinical trial for ischemic heart failure of reduced ejection fraction (HFrEF), which affects millions of patients in the United States. Th ...

TAMPA, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ: UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that management will participate in the following March 2026 investor conferences. Full details for each conference can be found below. Webull Digital Asset Treasury Crypto Webinar Date: March 12, 2026, 1:40 PM ET Speaker: Brian Rudick, Chief Strategy Officer Type: Virtual Presentation Webcast: https://ir.upe ...